𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

✍ Scribed by Elias Jabbour; Guillermo Garcia-Manero; Nicolas Batty; Jenny Shan; Susan O'Brien; Jorge Cortes; Farhad Ravandi; Jean-Pierre Issa; Hagop Kantarjian

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
199 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Decitabine improves patient outcomes in
Decitabine improves patient outcomes in myelodysplastic syndromes : Results of a phase III randomized study
✍ Hagop Kantarjian; Jean-Pierre J. Issa; Craig S. Rosenfeld; John M. Bennett; Mahe πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 204 KB

## Abstract ## BACKGROUND Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters.